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Abstract  
Aims: To perform a systematic literature review and meta-analysis of clinical risk factors for 
sudden cardiac death in childhood hypertrophic cardiomyopathy.  
Methods: Medline and PubMed databases were searched for original articles published in English 
from 1963 through to December 2015 which included patients under 18 years with a primary or 
secondary end-point of either sudden cardiac death (SCD) or equivalent (aborted cardiac arrest or 
appropriate ICD discharge) or cardiovascular death (CVD). 
Results: Twenty five studies (3394 patients) met inclusion criteria. We identified four conventional 
major risk factors which were evaluated in at least 4 studies and found to be statistically associated 
with an increased risk of death in at least 2 studies: previous adverse cardiac event (pooled hazard 
ratio 5.4 (95% CI 3.67-7.95), p <0.001 ); non-sustained ventricular tachycardia (pooled hazard ratio 
2.13 (95% CI 1.21-3.74), p=0.009); unexplained syncope (pooled hazard ratio 1.89 (95% CI 0.69-
5.16), p=0.22);and extreme left ventricular hypertrophy (pooled hazard ratio 1.80 (95% CI 0.75-
4.32), p=0.19). Left atrial diameter did not meet the major risk factor criteria, however is likely to 
be an additional significant risk factor. ‘Minor’ risk factors included a family history of sudden 
cardiac death, gender, age, symptoms, ECG changes, abnormal blood pressure response to exercise 
and left ventricular outflow tract obstruction. 
Conclusions: A lack of well-designed, large population based studies in childhood hypertrophic 
cardiomyopathy means the evidence-base for individual risk factors is not robust. We have 
identified four clinical parameters which are likely to be associated with increased risk of SCD, 
SCD-equivalent event or CVD. Multi-centre prospective studies are needed to further determine 
their relevance in predicting SCD in childhood HCM and to identify novel risk markers. 
 
 
Condensed abstract:  
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A systematic review and meta-analysis of clinical risk factors predicting sudden cardiac death 
(SCD) in childhood hypertrophic cardiomyopathy (HCM) was performed identifying four ‘major’ 
factors: previous adverse cardiac event; non-sustained ventricular tachycardia; syncope and extreme 
left ventricular hypertrophy. Well-designed multi-centre studies are required in the future to 
confirm these findings.  
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Background 
 
Hypertrophic cardiomyopathy (HCM) is defined as left ventricular hypertrophy (LVH) in the 
absence of loading conditions (hypertension, valve disease or congenital heart disease) sufﬁcient to 
cause the observed abnormality1. The true prevalence of HCM in childhood is unknown but is 
estimated to be in the region of 2.9 per 100,0002-4. The aetiology of paediatric HCM is 
heterogeneous, and includes inborn errors of metabolism, malformation syndromes and 
neuromuscular disorders. However, most cases of HCM are caused by mutations in cardiac 
sarcomere protein genes, even in young children5,6. 
 
The long-term prognosis of HCM in childhood is highly variable and depends to a large degree on 
the underlying aetiology. Estimates for sudden cardiac death (SCD) rates in childhood HCM vary 
widely and recent epidemiological studies have reported rates of between 1 and 7.2% per year7–12. 
One of the greatest challenges in managing young patients with HCM is the identification of 
individuals at highest risk of adverse events. Risk factors for SCD in adult HCM patients are well 
described and, recently, a novel risk model (HCM RISK-SCD) has been developed to improve the 
targeting of implantable cardioverter-defibrillators (ICDs)14. However, this is not validated for 
patients under 16 years of age and the value of conventional “adult” risk markers in children is 
uncertain.  ICDs have been shown to be effective at aborting malignant arrhythmias in childhood 
HCM8,13 but this is at the expense of a much higher rate of complications compared to adults15. This 
highlights the need for a greater understanding of risk factors for SCD in childhood HCM to allow 
clinicians to robustly identify patients for primary prevention therapy. We, therefore, performed a 
systematic review and meta-analysis of the published literature to evaluate published risk factors in 
childhood HCM.  
 
Methods 
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Study selection 
The online MEDLINE database was searched using PubMed through the MeSH (Medical Subject 
Headings) terms “((hypertrophic cardiomyopathy) AND (death OR sudden death OR cardiac death 
OR outcome OR prognosis OR risk factors) AND (children OR childhood OR young OR 
paediatric)). All searches were limited to: original articles written in English, patients <18 years, 
published from 1963 through to December 2015. This initial search strategy was supplemented by a 
manual search of the references for included papers and the most recent review articles.  
 
Inclusion criteria  
Studies reporting on a cohort of HCM patients with a primary or secondary end-point of either 
sudden cardiac death (SCD), SCD-equivalent event (aborted cardiac arrest or appropriate ICD 
discharge) or cardiovascular death (CVD) were included. Studies with an end-point of CVD 
secondary to heart failure alone were excluded.  
We required that studies explored possible associations between clinical risk factors and survival, 
therefore studies with no estimates of association were excluded (this included case-reports and 
letters). We excluded those in which the patient cohort were exclusively infants (<1 year), or had a 
mixed adult and paediatric population with <75% of cohort under 18 years without separate 
analysis of paediatric data, or limited to rarer phenocopies such as Noonan syndrome or related 
disorders. As the study focused on clinical risk factors, studies exploring the use of genotyping or 
invasive markers to predict survival were excluded.  
 
Data collection: 
The titles and abstracts of all studies identified by the search strategy were reviewed by two 
independent researchers (GN and NC) to determine eligibility. All eligible studies were read in full 
by the same two independent researchers. The following data were extracted from all included 
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studies: patient characteristics (age and sex); study design; risk factor definition; length of follow up 
and number of patients lost to follow-up; univariate and/or multivariable Cox regression analysis; 
event count data and type of endpoint (SCD, SCD-equivalent event, CVD). A quality assessment for 
each included study was performed in line with the QUORUM (Quality of Reporting of Meta-
analyses) statement16. 
Survival analyses were not reported in all studies and for these count data were extracted in order to 
compute odds ratios for SCD. For the major risk factors, pooled estimates for the hazard ratio 
and/or odds ratio are reported. Average hazard ratios/odds ratios were not calculated for minor risk 
factors because of the low number of studies. 
 
Statistics:  
Random-effects meta-analysis was performed to combine the data from the included studies while 
accounting for between-study heterogeneity. The outcome of time to SCD (event of interest as 
described above) was addressed. SCD was also considered as a dichotomous outcome. In the first 
case, the results from each study’s Cox proportional hazards regression analysis were combined 
using the generic inverse-variance (IV)  method. Adjusted and unadjusted hazard ratios were pooled 
together. When SCD was considered as a dichotomous outcome, the event counts and the numbers 
of those with and without the risk factor under investigation were extracted from the included 
studies in order to estimate the study odds ratio. Pooled odds ratios were calculated using the 
Mantel-Haenszel (M-H) method. We report the pooled odds ratio and pooled hazard ratio for each 
risk factor with a 95% confidence interval for each summary estimate. We also report I2, the 
percentage of variability in estimates due to heterogeneity between the studies. A significance level 
of 5% (p value < 0.05) was used for analysis. The analysis was carried out using Review Manager 
(version 5.3)37  
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Results 
 
Figure 1 summarises the search result. Briefly, the initial search identified 820 unique studies. By 
reading the titles and abstracts 787 were excluded. The full text version was evaluated for the 
remaining 33 articles. This excluded a further 8 articles. Reasons for exclusion are detailed in 
Figure 1. Data were extracted from the remaining 25 articles which met inclusion criteria (table 1). 
Of the included studies, the end-point measured was SCD in 10 studies (40%), all cause CVD in 7 
studies (28%) and both SCD and CVD in the remaining 8 studies (32%). In total, 23 clinical risk 
factors were studied. The definition of risk factors used in included studies is detailed in table 2.  
 
For the purpose of analysis we divided the reported risk factors into 2 groups: probable/major risk 
factors (defined as being investigated as a potential risk factor in at least 4 studies and significantly 
associated with the end point in at least 2 univariate or multivariable analyses); and possible/minor 
risk factors (defined as being significantly associated with the end-point in 1 univariate or 
multivariable analysis study).  
 
Major risk factors 
 
Previous adverse cardiac event (aborted cardiac arrest or sustained VT) 
 
Five studies12,17–20  evaluated the prognostic value of a previous adverse event (AE) for SCD12,18–20  
or  CVD17.  A significant association with SCD was shown in two univariate analyses (p<0.000119, 
p=0.00420), and one multivariable analysis (p<0.00120). Kamp et al.18 described a small cohort of 
patients with previous ICD implantation in which a previous AE was not significant for SCD, 
however this study was underpowered to detect a difference. Decker et al.17 did not find an 
association with all CVD, however SCD was not analysed separately. The hazard ratio is 5.4 (95% 
8 
 
CI 3.67-7.95), p<0.001, I2=0% (figure 2a). The odds ratio estimate for previous AE is 5.06 (95% CI 
2.11-12.17), p<0.001, I2=0% (figure 2b). 
 
 
Syncope 
 
Syncope was investigated as a potential risk factor for SCD in seven studies10,12,15,18-21 and for CVD 
in one study17. Three of the identified studies reported a significant relationship between 
unexplained syncope/pre-syncope and SCD10,19,21. No significant association was seen between 
syncope and CVD17 . The hazard ratio is 1.89 (95% CI .69-5.16), p=0.22, I2=46% (figure 3a). The 
odds ratio estimate for syncope is 2.64 (95% CI 1.21-5.79), p=0.02, I2=40% (figure 3b). 
 
 
Non-sustained ventricular tachycardia (NSVT) 
 
Six studies evaluated the predictive value of NSVT detected during ambulatory 
electrocardiographic (ECG) monitoring for SCD12,15,19,20 or CVD17,22. Two found a significant 
relationship between NSVT and SCD12,15, with a further study reporting non-significance of NSVT 
but significance for inducible VT during an electrophysiology study (EPS)19. No studies reported a 
significant association of NSVT and CVD17,22.  
The pooled hazard ratio was 2.13 (95% CI 1.21-3.74), p=0.009, I2=19% (figure 4a). The pooled 
odds ratio estimate for NSVT is 2.05 (95% CI .98-4.28), p=0.06, I2=11% (figure 4b). 
 
 
Left ventricular hypertrophy 
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Left ventricular hypertrophy (LVH) was the mostly frequently assessed risk marker12,15,17–20,22–28, 
however the measurement of LVH was highly variable. The most common measure of LVH was 
interventricular septal thickness (IVST)12,19,20,22–27, for which 2 studies reported a significant 
association with SCD19,26 and a further study a correlation with CVD22. Six studies evaluated the 
predictive value of LV posterior wall thickness (LPWT)20,22,23,25,27,28 of which 4 showed a 
significant correlation between increasing LPWT and all cause CVD22,23,27,28 and 1 study showed an 
association with SCD23. A left ventricular wall thickness/cavity ratio >0.3 was found to be 
significantly associated with CVD in the two studies reporting this measurement20,26. No studies 
analysed its relationship with SCD. Finally, extreme LVH (as defined table 2) was evaluated in five 
studies15,17,18,20,22 and found to be statistically associated with SCD in one third of studies using this 
outcome measure15 and both studies looking at CVD17,22. Another study showed increased risk of 
SCD with increasing LV wall thickness25. The hazard ratio for extreme LVH is 1.80 (95% CI .75-
4.32), p=0.19, I2=21% (Figure 5a). The odds ratio estimate for extreme LVH is 1.70 (95% CI .85-
3.40), p=0.13, I2=31% (Figure 5b). 
 
 
Minor risk factors  
 
Family History of Sudden Cardiac Death  
 
A family history (FHx) of sudden cardiac death (SCD) was evaluated as a risk factor in seven 
studies12,17–20,22,27. Only one study reported a statistically significant association with SCD (HR 
10.6, 95%CI 1.2-90.2, p=0.03)18. 
 
Gender 
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Gender was investigated as a predictive factor for death in five studies18,22,23,26,27. The majority did 
not demonstrate a significant relationship, However, Lipshultz et al.27 reported an increased risk of 
CVD in female patients (HR 2.4, CI: 1.09-5.17, p=0.03). 
 
Age 
 
Age at presentation or diagnosis was investigated as a potential risk factor for death in eleven 
studies7,11,12,19,20,22–24,26–28. Presentation in infancy (<1 year) was consistently associated with an 
increased risk of CVD, likely secondary to congestive cardiac failure7,22,28; however, outside 
infancy, the majority of studies found no association between age and the risk of death12,20,22–24,27. 
Ostman Smith et al. reported an increased risk of SCD if younger at presentation26. In contrast, one 
study reported an increased risk of CVD in children presenting above 13 years19,and another if 
between the ages of 9-14 at presentation11. 
 
Symptoms 
 
Eight studies compared the risk of death in symptomatic and asymptomatic patients12,17,20,21,24,26–28, 
however the definition of symptomatic patients was highly variable. The presence of symptoms of 
congestive cardiac failure at presentation was significant in predicting an increased risk of CVD in 
3 out of 4 studies with this end-point20,21,27. One study reported that other symptoms (including 
chest pain and palpitations) were also significantly associated with increased risk of CVD26. Only 3 
studies assessed symptoms as a risk factor for SCD12,24,26, of which only one found a significant 
association with SCD (HR1.7 (95% CI 0.80–3.6) p = 0.1724). However, this was a composite 
measure including syncope, previous AE, chest pain, tachycardia and dizziness and therefore may 
not be an independent risk factor. 
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ECG changes 
 
Five studies12,20,26,29,30 that assessed the prognostic value of ECG changes were identified. QTc 
dispersion was analysed in two studies and found to be associated with SCD in both (HR 3.2, CI: 
1.5-6.6, p=0.004220, RR 1.61, CI; 1.24-2.08, p=0.000312). Other ECG parameters included RS sum, 
which was analysed in one study and found to be significantly associated with SCD (HR 8.4 (95% 
CI 2.2-33.2) p=0.0012)26, and heart rate variability, which correlated with SCD in both studies29,30, 
however only reached statistical significance in one29.  
 
Abnormal blood pressure response to exercise   
 
Blood pressure response to exercise was evaluated as a potential risk factor in 4 studies17–20, 
however an abnormal blood pressure response to exercise (ABPE) as defined in table 2 was not 
found to be significantly associated with SCD. One study reported a significant relationship 
between ABPE and cardiovascular death (HR 9.6 (95% CI 1.0-93.1) p=<0.03)17. 
 
Left ventricular outflow tract obstruction (LVOTO) 
 
Left ventricular outflow tract obstruction (LVOTO) was assessed as a potential risk factor for SCD 
in two studies, and CVD in four studies12,17,20,22,28,31. A significant association with CVD was 
reported in one study (p=0.04)22. Ziowlowska et al.20 reported a higher risk of SCD with increasing 
LVOTO gradient (p=0.04); however, whilst in the adult literature a gradient above 30mmHg is 
predictive for SCD, a gradient above 30mmHg was not predictive for SCD in this study.  
 
Left atrial (LA) size 
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Left atrial size was investigated as a risk factor for SCD in three studies20,24,25 and CVD in two 
studies20,24. Increased left atrial size was significantly correlated with SCD in two studies (HR 3.125 
(95%CI 1.45-6.74) p=0.00120, HR 3.4, CI: 1.1-11.2, p=0.04924). Therefore, although LA size does 
not meet the criteria for classification as a major risk factor, it is likely to be a significant predictor 
for SCD.  
 
Restrictive physiology 
 
Three studies20,24,25 analysed the predictive value of echocardiographic markers of restrictive 
physiology for SCD. The measurement of restrictive physiology varied and included: septal 
E/E’24,25, mitral inflow Doppler E/A ratio20,24 and LA enlargement without evidence of LV 
dilatation24. McMahon et al.25 reported that early transmitral left ventricular filling velocity 
(E)/septal Ea ratio predicted the risk of SCD (HR 6, p<0.001) and Maskatia et al.24 reported 
echocardiographic findings associated with  restrictive physiology to beassociated with a 3.8 fold 
increase in the risk of SCD (HR 3.8, p =0.302). 
  
Strain 
 
Strain as assessed by echocardiography was investigated as a risk factor for SCD in only one study 
which reported a significant association of reduced global strain and increased risk of SCD (OR 
1.13, CI 1.00-1.27) but a non-significant relationship between SCD and longitudinal or radial 
strain32. 
 
24 hour blood pressure monitoring 
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Abnormal 24 hour ambulatory blood pressure monitoring was investigated as a risk factor for SCD 
in a single study in which a significant association was shown between an abnormal BP ratio (lower 
systolic BP in the morning) and risk of SCD30. 
 
Late Gadolinium Enhancement on Cardiac Magnetic Resonance (CMR) imaging 
3  studies 38,39,40 were identified that looked at the predictive value of late gadolinium enhancement on CMR as a 
risk factor for SCD in childhood HCM.  They reported an increased incidence of LGE in patients with adverse 
outcomes. However, this did not reach statistical significance. In contrast the presence of LGE was statistically 
associated with increased LV wall thickness/mass. 
 
Discussion  
 
Risk factors for SCD in adult HCM patients are well-described and current European and American 
guidelines describe validated risk stratification algorithms for primary prevention. The American 
College of Cardiology Foundation/American Heart Association currently recommends that ICD 
implantation is reasonable if one major risk factor (Family history of SCD, LV wall thickness 
>30mm or unexplained syncope) is present and could be considered if two or more other risk 
factors are present34. In comparison, the European Society of Cardiology has endorsed the use of a 
new SCD risk prediction model (HCM Risk-SCD)14 which provides an individualised estimate for 
5 year SCD risk utilising predictor variables associated in multi-variable analyses. However, these 
algorithms have not been validated in children and younger teenagers. 
 
This study is, to our knowledge, the first systematic review of potential risk factors for SCD in 
childhood HCM. Although a large number of potential risk factors for SCD in childhood HCM 
have been reported in the literature over the past 30 years, the lack of consistent definitions and 
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well-designed, large population based studies means that the evidence for individual risk factors is 
not robust.  
 
Within both current European and American guidelines for the management of adults with HCM, 
short sections on the risk of SCD in childhood HCM 33-35 recommend the use of four major risk 
factors to predict SCD: maximum left ventricular wall thickness >30mm or z score >+6; 
unexplained syncope; NSVT; and family history of SCD. ICD implantation is recommended for 
primary prevention of SCD for those with 2 or more major risk factors8,15,17,26,35,36. The present 
systematic review supports the inclusion of unexplained syncope and NSVT as likely major risk 
factors for SCD in paediatric HCM. The measurement and definition of LVH varied between 
studies; however, severe LVH was found to be associated with SCD in several studies although 
pooled odds/hazard ratios were not significant at the 5% significance level. Interestingly, only one 
study showed a significantly increased risk of death with a LV wall thickness >30mm/Z score >+6, 
the definition endorsed by the ESC guidelines. The most clinically important measure of LVH and 
appropriate cut off to measure increased risk in paediatric HCM needs further investigation.  
 
A family history of SCD was not classified as a major risk factor for paediatric HCM in our 
analysis as only one paper reported a statistical relation with sudden death. The ESC 
recommendations for the use of family history in children was based on a study36 that was excluded 
from our review because less than 75% patients were below 18 years of age in the cohort. There is 
significant evidence supporting a family history of SCD as a risk factor in adult HCM; however 
there is currently a lack of data to support its role in paediatric HCM. Possible explanations for this 
observation may include a higher prevalence of de novo mutations in paediatric HCM, a small 
proportion of sarcomeric positive patients and insufficient reporting of family history in included 
studies. This needs further evaluation in future large scale paediatric cohort studies.  
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In adults, evidence supports additional risk factors such as left atrial diameter, left ventricular 
outflow tract obstruction or an abnormal blood pressure response to exercise, which can modify an 
individuals’ risk. Our data suggest that, in addition to the four ‘major’ risk factors described, other 
clinical variables are also likely to be useful for risk stratification in childhood. These additional 
risk factors may be the same in adulthood and childhood, for example left atrial size, which was 
significantly associated with SCD in 2 out of 3 studies. However, other variables such as LVOTO 
and an abnormal BP response to exercise may not be as important in childhood compared to 
adulthood. Further studies are required to explore the potential association between these risk 
factors and risk of SCD in childhood HCM.  
 
The validated SCD risk prediction model (HCM RISK-SCD)14 described above, which provides an 
individualised estimate for 5 year SCD risk, is not validated for patients under 16 years of age. 
Additionally, although it is validated for patients aged 16-18years, this group of patients constituted 
a small proportion of the cohort (n=82/3675, 2%), and therefore this group of patients require 
further evaluation. This systematic review has provided evidence that, whilst some of the validated 
adult risk factors may be applicable to risk stratification in childhood HCM, such as LVH or 
syncope, others, such as abnormal blood pressure response to exercise, may be less relevant. The 
results of this systematic review suggest that further research is needed to develop a validated 
paediatric-specific risk prediction model for SCD in HCM.   
 
The number of studies included in this meta-analysis is small, and of these, all but one was a 
retrospective cohort study. It is, therefore, limited by the intrinsic problems of retrospective studies, 
including missing and incomplete information. Childhood HCM is a rare disease and many of the 
included studies were small; all but 3 of the studies had less than 150 participants. Furthermore, the 
patient populations were heterogeneous, making comparisons between groups challenging. Adverse 
outcomes in this population are rare and outcomes are highly variable depending on the underlying 
16 
 
aetiology, necessitating long follow up periods to identify prognostic risk factors. Many of the 
included studies had low event counts, which is likely to have reduced their power to detect 
differences between groups. Additionally, as the patients in included studies were often recruited 
from a small number of highly specialised tertiary services, which care for highly symptomatic 
individuals, it is possible that this patient group may have more severe disease and that duplication 
of patient data may have occurred in different studies. Collectively these limitations mean that the 
applicability of the results of this study to individual patients and the wider HCM population is 
difficult to determine.  
 
Finally, comparison between studies was complicated by differences in the study design, definition 
of individual risk factors (including different Z score calculators) and study end-points. Diverse 
definitions were a particular problem for studies investigating the predictive role of ‘symptoms’ and 
‘LVH’ for SCD. The use of ‘appropriate ICD therapy’ as a surrogate marker for SCD, although 
well established in both adult and paediatric studies, is a possible source of error as it does not 
account for inappropriate ICD therapy which has been reported to be more common in the 
paediatric population. Pooled estimates for average hazard and odds ratios were calculated; 
however the precision of estimates reported in the included studies is low as is the number of 
studies included. This is reflected in the width of the confidence interval for the pooled ratios. 
These estimates should be interpreted with caution due to the small number of studies and 
heterogeneity of included studies, and exclusion of studies with no estimates of association. 
 
 Conclusions: 
We have identified 4 ‘Major’ risk factors that have been evaluated in at least 4 studies and found to 
be statistically associated with increased risk of death in at least 2 studies: Previous adverse cardiac 
event; NSVT, syncope and LVH. Pooled estimates of risk (odds/hazard ratio) were significant for 
previous adverse cardiac event, NSVT and syncope, however did not reach significance at 5% level 
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for extreme LVH. A significant number of other potential ‘Minor’ risk factors have been described, 
however many of these need further evaluation to determine their relevance in predicting SCD in 
childhood HCM. 
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